Antitumor activity of methotrexate‐albumin conjugates in rats bearing a Walker‐256 carcinoma

@article{Wunder1998AntitumorAO,
  title={Antitumor activity of methotrexate‐albumin conjugates in rats bearing a Walker‐256 carcinoma},
  author={Andreas Wunder and Gerd Stehle and Hans Hermann Schrenk and Gernot Hartung and Dieter L. Heene and W Maier-borst and Hannsjörg Sinn},
  journal={International Journal of Cancer},
  year={1998},
  volume={76}
}
We have recently reported that albumin accumulates in solid tumors and serves there as a source of nitrogen and energy. Methotrexate‐albumin conjugates [MTX(1)‐RSA] derivatized at a molar ratio of 1:1 differ favorably from original MTX in terms of plasma presence and tumor uptake. The purpose of this study was to evaluate the therapeutic efficacy of these novel conjugates in a comparative study with low m.w. MTX in Sprague‐Dawley rats bearing a Walker‐256 carcinoma. The maximum tolerated dose… 

Pre‐clinical evaluation of a methotrexate–albumin conjugate (MTX‐HSA) in human tumor xenografts in vivo

The improved therapeutic effects seen in 3 xenograft models under MTX‐HSA treatment are promising and might be due to specific accumulation of the compound in solid tumors owing to their enhanced permeability and retention effect.

Efficacy and tolerability of an aminopterin–albumin conjugate in tumor-bearing rats

In this comparative study, the AMPT–SA conjugate showed high antitumor activity in vivo and a favorable toxicity compared to low-molecular-weight AMPT, which seems to be an effective tool for selective tumor drug targeting.

ArthritisTherapeutic Approach for Rheumatoid Albumin-Based Drug Delivery as Novel

We reported recently that albumin is a suitable drug carrier for targeted delivery of methotrexate (MTX) to tumors. Due to pathophysiological conditions in neoplastic tissue, high amounts of albumin

Albumin-Based Drug Delivery as Novel Therapeutic Approach for Rheumatoid Arthritis1

We reported recently that albumin is a suitable drug carrier for targeted delivery of methotrexate (MTX) to tumors. Due to pathophysiological conditions in neoplastic tissue, high amounts of albumin

Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX.

The data show that the effectiveness of MTX-HSA in CIA is superior to MTX and that both drugs act synergistically, suggesting that they might be one of the potential target cells of this novel anti-arthritic treatment approach.

Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.

  • G. HartungG. Stehle W. Queisser
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1999
This first Phase I study of MTX-HSA to determine dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) in a weekly regimen was well tolerated and tumor responses were seen, with no signs of toxicity or drug accumulation seen.

A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy

MTX-HSA was generally well tolerated and can be given on an outpatient basis, but no objective responses were seen in patients with metastatic RCC who had progressed after previous immunotherapy.

Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo

Treatment with MTX or MTX-HSA significantly ameliorates cartilage destruction in the SCID mouse model for human RA.

Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation

Albumin has shown remarkable promise as a natural drug carrier by improving pharmacokinetic (PK) profiles of anticancer drugs for tumor-targeted delivery. The exogenous or endogenous albumin enhances

References

SHOWING 1-10 OF 33 REFERENCES

Pharmacokinetics of methotrexate–albumin conjugates in tumor-bearing rats

The potential therapeutic benefit of the MTX(1)-RSA conjugate lies in its very long tumor exposure time and its improved tumor accumulation rate compared to conventional MTX.

Evolution of acute lymphoblastic leukemia in mice treated with carrier-bound methotrexate and levamisole.

In vivo a single dose of 15 mg/kg MTX, which lacked therapeutic effect on tumor-bearing mice, increased the mean survival time (MST) of the animals when given as MTX-BSA.

The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. IV. Therapy of murine melanoma B16 by human serum albumin-methotrexate derivative.

It was found that the growth of tumor was slower after therapy with the HSA-MTX derivative than after free MTX treatment, and the reduction in tumor size recorded on day 21 after tumor transplantation was more significantly pronounced than in case of freeMTX treatment.

Characterization of in‐vitro drug release and biological activity of methotrexate‐bovine serum albumin conjugates

Two series of methotrexate (MTX)‐bovine serum albumin (BSA) conjugates have been prepared and retain a degree of antineoplastic activity in‐vitro, but this might be related to the small fraction of MTX that is tightly physically bound.

The interaction of carrier-bound methotrexate with L1210 cells.

MTX was as effective as free MTX and MTX bound to bovine serum albumin (MTX-BSA) in prolonging the life span of BDF1 mice bearing the L1210 tumor, suggesting that MTX can act as an effective chemotherapeutic agent when covalently bound to a variety of proteins.

Passive tumor targeting of soluble macromolecules and drug conjugates.

  • L. Seymour
  • Biology, Chemistry
    Critical reviews in therapeutic drug carrier systems
  • 1992
The "enhanced permeability and retention effect" (EPR effect) has been studied extensively, and it is thought to constitute the mechanism of action of SMANCS (styrene-maleic/anhydride-neocarzinostatin), now in regular clinical use in Japan for the treatment of hepatoma.

The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing.

It was concluded that although the HSA-MTX derivative was more toxic than free MTX, its therapeutic activity was better and all animals survived without tumor.

The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. V. Alternative method for preparation of serum albumin-methotrexate derivative.

An alternative method for the preparation of human serum albumin-methotrexate derivative (HSA-MTX) using N-hydroxysuccinimide ester of methotrexate (MTX) was compared with that using the